Abstract

Background

Patients with schizophrenia can generally manifest a broad variety of primary negative symptoms. The current study aimed to assess the efficacy and tolerability of resveratrol add-on therapy in the treatment of negative symptoms in patients with stable schizophrenia.

Methods

In a randomized, double-blind, and placebo-controlled setting, schizophrenia patients were assigned to receive either 200 mg/d resveratrol or matched placebo in addition to a stable dose of risperidone for 8 weeks. Patients were assessed using the positive and negative syndrome scale, the extrapyramidal symptom rating scale, and Hamilton Depression Rating Scale over the trial period. The primary outcome was considered as the change in positive and negative subscale score from baseline to week 8 between the treatment arms.

Results

A total 52 patients completed the trial (26 in each arm). Baseline characteristics of both groups were statistically similar (P > .05). Despite the statistically similar behavior of positive symptoms between the groups across time (Greenhouse-Geisser corrected: F = 1.76, df = 1.88, P = .180), the resveratrol group demonstrated greater improvement in negative, general psychopathology, and total scores (Greenhouse-Geisser corrected: F = 12.25, df = 2.04, P < .001; F = 5.42, df = 1.56, P = .011; F = 7.64, df = 1.48, P = .003). HDRS scores and its changes, ESRS score, and frequency of other complications were not significantly different between resveratrol and placebo groups.

Conclusion

Adding resveratrol to risperidone can exhibit remarkable efficacy and safety in terms of management of schizophrenia-related negative symptoms.

中文翻译：

---

白藜芦醇辅助治疗稳定型精神分裂症患者的阴性症状：一项双盲、随机安慰剂对照试验

摘要

背景

精神分裂症患者通常可以表现出各种各样的原发阴性症状。目前的研究旨在评估白藜芦醇附加疗法治疗稳定型精神分裂症患者阴性症状的疗效和耐受性。

方法

在随机、双盲和安慰剂对照的环境中，精神分裂症患者被分配接受 200 mg/d 白藜芦醇或匹配的安慰剂以及稳定剂量的利培酮治疗 8 周。在试验期间，使用阳性和阴性综合征量表、锥体外系症状评定量表和汉密尔顿抑郁评定量表对患者进行评估。主要结果被认为是治疗组之间从基线到第 8 周的正负分量表评分的变化。

结果

共有 52 名患者完成了试验（每组 26 名）。两组的基线特征在统计学上相似（P > .05）。尽管随着时间的推移，各组之间阳性症状的行为在统计学上相似（Greenhouse-Geisser 校正：F  = 1.76，df = 1.88，P = . 180），但白藜芦醇组在阴性、一般精神病理学和总分方面表现出更大的改善（Greenhouse-Geisser - Geisser 修正：F  = 12.25，df = 2.04，P < . 001；F  = 5.42，df = 1.56，P = . 011；F = 7.64，df = 1.48，P = .003)。HDRS 评分及其变化、ESRS 评分和其他并发症的频率在白藜芦醇组和安慰剂组之间没有显着差异。

结论

在管理精神分裂症相关阴性症状方面，在利培酮中加入白藜芦醇可显示出显着的疗效和安全性。